CB-839: A Potent GLS1 Inhibitor for Cancer Therapy Research and Development
Explore the potential of CB-839, a key player in targeting cancer metabolism for groundbreaking therapies.
Get a Quote & SampleProduct Core Value
CB-839
CB-839 is a potent, selective, and non-competitive inhibitor of glutaminase GLS1, making it a crucial tool in cancer metabolism research. Its ability to target glutamine addiction in cancer cells offers a novel therapeutic avenue. We offer this as a key pharmaceutical intermediate for drug discovery programs.
- This potent GLS1 inhibitor demonstrates significant antiproliferative activity in triple-negative breast cancer cell lines.
- CB-839 exhibits selective inhibition of GLS1 over GLS2, a critical factor for targeted therapies.
- The compound shows significant antitumor activity as a single agent in patient-derived xenografts, supporting its therapeutic potential.
- CB-839 is orally bioavailable, a desirable characteristic for clinical drug development in cancer treatment.
Key Advantages Offered
Targeted Cancer Metabolism Inhibition
Leveraging CB-839 in your research helps target the metabolic dependencies of cancer cells, offering a novel strategy for treatment.
Potent and Selective Action
The high potency and selectivity of CB-839 for GLS1 ensures precise targeting of cancer pathways with minimal off-target effects, supporting precise drug discovery.
Preclinical Efficacy Demonstrated
With proven antiproliferative and antitumor activity in preclinical models, CB-839 serves as a strong candidate for further development in oncology.
Key Applications
Oncology Drug Discovery
Utilize CB-839 to explore novel therapeutic strategies by inhibiting glutaminolysis in various cancer types, advancing your drug development pipeline.
Metabolic Pathway Research
Investigate the role of glutamine metabolism in cancer progression and drug resistance using this potent GLS1 inhibitor.
Preclinical Cancer Studies
Employ CB-839 in xenograft models to evaluate its efficacy and potential synergies with other chemotherapeutic agents.
Biochemical Assays
Use CB-839 as a standard in biochemical assays to measure GLS1 activity and screen for new inhibitors.